Molecure

Molecure is a clinical stage biopharmaceutical company based in Poland. Since its establishment in 2012, the company has been dedicated to utilizing its world-leading medicinal chemistry capabilities to address unmet medical needs. Molecure's approach involves discovering and developing first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases.

The company has established a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, positioning itself at the forefront of innovation in biotechnology. Notably, Molecure's lead drug candidate is OATD-01, a first-in-class dual chitinase inhibitor targeted at the treatment of fibrotic and inflammatory diseases, including interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis (IPF).

With its groundbreaking research, Molecure has garnered significant attention from investors, securing a PLN18.00M Series A investment on 08 March 2017. This funding has propelled the company's advancements, enabling it to advance clinical trials and further develop its promising pipeline.

Molecure's commitment to pioneering pharmaceutical solutions is evident in its ongoing initiatives, including the phase II study in sarcoidosis patients, which commenced in March 2024. Additionally, the company's groundbreaking work extends to cancer treatment, with OATD-02, the first and only dual-acting, highly potent arginase inhibitor in cancer development, currently undergoing a Phase 1 clinical trial following its initiation in March 2023.

As a testament to its dedication to innovation, Molecure is listed on the Warsaw Stock Exchange (ticker: MOC), highlighting its strong presence in the biotechnology sector. The company's headquarters and laboratories are situated in Warsaw, Poland, with additional laboratories in Łódź, further exemplifying its commitment to expanding its research and development capabilities.